


## WAY-204688

<b>Cat. No.:</b>	HY-19498		
<b>CAS No.:</b>	796854-35-8		
<b>Molecular Formula:</b>	C <sub>34</sub> H <sub>31</sub> F <sub>3</sub> N <sub>2</sub> O <sub>2</sub>		
<b>Molecular Weight:</b>	556.62		
<b>Target:</b>	NF-κB		
<b>Pathway:</b>	NF-κB		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (179.66 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	1.7966 mL	8.9828 mL	17.9656 mL
		5 mM	0.3593 mL	1.7966 mL	3.5931 mL
10 mM		0.1797 mL	0.8983 mL	1.7966 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (4.49 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	WAY-204688 is an estrogen receptor (ER-α) selective, orally active inhibitor of NF-κB transcriptional activity with an IC <sub>50</sub> of 122 ± 30 nM for NF-κB-luciferase (NF-κB-luc) in HAECT-1 cells.	
<b>IC<sub>50</sub> &amp; Target</b>	NF-κB-luc 122 nM (IC <sub>50</sub> , in HAECT-1 cell)	NF-κB
<b>In Vitro</b>	WAY-204688 is ER-dependent (activity seen only when hER is coexpressed with NF-κB-luciferase in human aortic endothelial cell lines (HAECT-1) cells). The interaction of WAY-204688 with ERα and ERβ is examined in vitro. WAY-204688 displaces [ <sup>3</sup> H]E2 from the ERα ligand binding domain protein (LBD) with IC <sub>50</sub> =2.43 μM and from the ERβ ligand binding domain protein (LBD) with IC <sub>50</sub> =1.5 μM <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

## In Vivo

WAY-204688 (5 mg/kg per day, po daily for 5 weeks) is evaluated in vivo for the ability to inhibit four proinflammatory genes (MHC, invariant chain (MHI), VCAM-1, RANTES, and TNF- $\alpha$ ). The effect of WAY-204688 on induction of the gene products and on uterine wet weight is compared to that of 17 $\alpha$ -ethinyl 17 $\beta$ -estradiol (EE at 10  $\mu$ g/kg per day) in the same paradigm. Further characterization of WAY-204688 is carried out in several preclinical models of inflammatory disease. In the Lewis rat adjuvant-induced arthritis model (AIA), WAY-204688 is active at a dose of 0.3 mg/kg per day, po<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Caggiano TJ, et al. Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid arthritis. J Med Chem. 2007 Nov 1;50(22):5245-8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA